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A B S T R A C T
NADPH-oxidases (NOXs) purposefully produce reactive-oxygen-species (ROS) and are found in most kingdoms
of life. The seven human NOXs are each characterized by a specific expression profile and a fine regulation to
spatio-temporally tune ROS concentration in cells and tissues. One of the best known roles for NOXs is in host
protection against pathogens but ROS themselves are important second messengers involved in tissue re-
generation and the modulation of pathways that induce and sustain cell proliferation. As such, NOXs are at-
tractive pharmacological targets in immunomodulation, fibrosis and cancer. We have studied an extensive
number of available NOX inhibitors, with the specific aim to identify bona fide ligands versus ROS-scavenging
molecules. Accordingly, we have established a comprehensive platform of biochemical and biophysical assays.
Most of the investigated small molecules revealed ROS-scavenging and/or assay-interfering properties to various
degrees. A few compounds, however, were also demonstrated to directly engage one or more NOX enzymes.
Diphenylene iodonium was found to react with the NOXs’ flavin and heme prosthetic groups to form stable
adducts. We also discovered that two compounds, VAS2870 and VAS3947, inhibit NOXs through the covalent
alkylation of a cysteine residue. Importantly, the amino acid involved in covalent binding was found to reside in
the dehydrogenase domain, where the nicotinamide ring of NADPH is bound. This work can serve as a
springboard to guide further development of bona fide ligands with either agonistic or antagonistic properties
toward NOXs.
1. Introduction
NADPH-oxidases (NOXs) are the only known enzymes whose spe-
cific function is reactive-oxygen-species (ROS) generation [1–4]. The
seven human NOXs share a conserved catalytic subunit, comprising an
N-terminal membrane domain that embeds two hemes, and a C-term-
inal cytosolic domain that binds the FAD prosthetic group and the
NADPH substrate [5]. The catalytic reaction starts with the reduction of
the flavin by NADPH. This is followed by a step-wise electron transfer
that leads to the reduction of the outer heme, located on the external
side of the membrane, where ROS generation takes place. NOX1, NOX2,
and NOX3 are regulated by various cellular proteins whereas NOX5 and
DUOXs are activated by calcium through additional calcium-binding
domains. NOX4 is the only constitutively active member of the family
[6]. Generally, NOXs coordinate cell damage, stress responses and
tissue regeneration. In particular, NOX2 is at the heart of the innate
immunity by eliminating bacterial threats in the phagocytes. High le-
vels of ROS derived from NOXs hyperactivity can result in genetic in-
stability followed by excessive proliferation, activation of the DNA-
damage response, proliferative senescence, and apoptosis [7–12]. With
their prototypical roles in ROS biology and redox signalling, NOXs are
attractive drug targets in inflammation, fibrotic and degenerative pro-
cesses, and cancer [3,13–15].
The functional complexity of NOXs suggests several potential me-
chanisms for a specific pharmacological response, such as the inhibition
of the enzyme assembly or the competition with the NADPH and O2
substrates. Diphenylene iodonium (DPI), di-2-thienyliodonium, and
apocynin have been the first molecules to be investigated as NOX
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inhibitors [16–22]. Indeed, DPI is widely employed in cell studies as
negative control to assess NOX activity. Besides being reported as a
flavoenzyme inhibitor [23], it has also been described as an inhibitor of
cytochrome P-450 reductase [17], xanthine oxidase [24] and nitric-
oxide synthase [25]. Suramin is a polysulfonated naphthylurea in use
since the 1920s as an agent against human trypanosomiasis [26]. Sur-
amin has also been reported to act as a NOX inhibitor in cell-free assays
with no inhibitory activity in NOX over-expressing cells, probably due
to lack of cell membrane permeability [27]. VAS2870 and VAS3947 are
extensively used in current literature although there are contradictory
observations regarding these compounds being bona fide NOX inhibitors
[27–31]. Phenothiazine derivatives have been described as anti-NOX
compounds and were studied with the aim of optimizing their chemical
structure in terms of NOX selectivity and decrease of its assay-inter-
ference profile [32]. Additionally, perhexiline (used in angina pectoris
and severe myocardial ischemia), plumbagin (a plant-derived naph-
thoquinone), ML090 (a quinoxaline derivative), 3-methyl-1-phenyl-2-
pyrazoline, and imipramine have been identified as a possible inhibitors
of NOXs [33–37]. Compounds such as GSK2795039 and GKT137831
(setanaxib) have been developed by pharmaceutical companies as
NOX2 or NOX4/NOX1 selective inhibitors and reached clinical eva-
luation [28,31,38–40]. Lastly, the peptide tat-gp91ds specifically blocks
the interaction between NOX2 and its activator p47phox [41]. Like-
wise, the inhibition of myocardial oxidative stress by statins,
blockbuster cholesterol-lowering drugs, has been ascribed to their in-
terference with Rac-induced NOX activation [42–44].
Scavenging of superoxide/hydrogen peroxide can represent an ad-
ditional strategy to interfere with the functions of NOXs. For instance,
phenanthridinones are antioxidant polyphenols with quinoid structures
and were reported as NOX inhibitors [45]. Celastrol is a natural product
used in the treatment of immunological diseases and has been described
as a compound blocking the ROS production associated to NOXs
[46,47]. Ebselen is a seleno-organic drug with antioxidant properties,
mainly functioning as an effective scavenger of organic hydroperoxides
[28,31,48]. However, there is also evidence of ebselen inhibiting ROS
production by disturbing the assembly of NOX2-activating regulatory
subunits [49,50].
Despite such a wealth of studies, a clear distinction between a ROS-
scavenging molecule and a true NOX binder is often missing and dis-
guised under the generic umbrella of the term “inhibitor”. The com-
plexity of detection and quantification of ROS, short-lived entities in
their biological milieu, has hindered the progress in the field.
Therefore, our understanding of the inhibitors’ mechanism of action
remains an open issue. The use of both orthogonal assays to validate the
results from the primary screens and control assays to monitor the di-
rect scavenging of ROS is of major importance. Additionally, direct
binding assays may be necessary to discriminate a bona fide NOX in-
hibitor from assay-interfering compounds. Here, we describe a com-
prehensive experimental workflow for NOX inhibitor development and
validation. We employed this strategy for the most widely used anti-
NOX compounds to validate efficacy and selectivity using both cell-free
and purified enzyme assays (Fig. 1). We found that most of the tested
NOX inhibitors have very substantial off-target effects, which in many
cases prohibit a convincing demonstration of their ability to directly
engage the NOX targets. However, we also show that a few of the
known NOX inhibitors are indeed proper NOX ligands with variable
degrees of isoform selectivities. These data will help the interpretation
of data arising from the usage of known NOX inhibitors and also lay
down a much-needed strategy for future NOX drug discovery and op-
timisation.
2. Materials and methods
2.1. Reagents
Roswell Park Memorial Institute (RPMI)1640 medium with L-
glutamine and sodium bicarbonate, penicillin, streptomycin, Lithium
Dodecyl sulfate (LiDS), MgCl2, flavin adenine dinucleotide disodium
salt hydrate (FAD-Na2), β-nicotinamide adenine dinucleotide 2′-phos-
phate reduced tetrasodium salt (NADPH), β-Nicotinamide adenine di-
nucleotide, reduced disodium salt hydrate (NADH), 1-methoxy phena-
zine methosulfate, Nitroblue tetrazolium, Sodium Azide, Phosphate-
Buffered Saline (PBS), Sodium Di-Hydrogen Phosphate (NaH2PO4·H2O),
Isopropyl β-D-1-thiogalactopyranoside, Sodium chloride, Glycerol.
Hepes, Leupeptin, Pepstatin, Phenylmethylsulfonyl fluoride.
SigmaFastTM Protease Inhibitor Cocktail Tablets EDTA-Free, Hemin
from Porcine, cytochrome c from equine heart, superoxide dismutase
(SOD), Amplex Red, Sodium dithionite and horseradish peroxidase,
Triton X-100 were purchased from Sigma-Aldrich. Potassium Phosphate
Dibasic (K2HPO4) was purchased from Carlo Erba Reagents.
Hydrochloric acid was purchased from Fluka. Magnesium Sulfate
(MgSO4) and Acetonitrile were purchased from Merck. Fetal bovine
serum was purchased from Invitrogen. 6-(4-methoxyphenyl)-2-methyl-
imidazo [1,2-a]pyrazin-3(7H)-one (MCLA) was purchased from
MedChemExpress. Non-fluorescent coumarin boronic acid (CBA) was
synthesized in house. All tested inhibitors were purchased from Sigma-
Aldrich except ML-090 (Cayman Chemical), GSK2795039
(MedChemExpress) and VAS3947 (Calbiochem). GKT136901 and
GKT137831 were a kind gift of GenKyoTex SA (France). The detergent
n-dodecyl-β-D-maltoside was purchased from Anatrace. Tat-gp91ds was
purchased from Anaspec. The DYKDDDDK-FLAG peptide was pur-
chased from China Peptides.
2.2. NOX expression and preparations
Bacterial NOX5 - The overexpression in E. coli and the preparation of
cell membranes for the FLAG-(His)8-SUMO N-terminally tagged
Cylindrospermum stagnale NOX5 was performed as reported [51]. The N-
terminally strep-tagged dehydrogenase domain (residues 413–693; wild
type and C-terminal mutant) and the FLAG-(His)8-SUMO N-terminally
tagged transmembrane domain (residues 209–412; wild type and
R256S mutant) were expressed and purified as described [5]. The
C668S mutant of the dehydrogenase was prepared following the same
protocols.
Human NOX2 membrane preparation and purification of cytosolic fac-
tors - X-CGD PLB-985 cells, transduced with the RD114-pseudotyped
MFGS-gp91phox vector (PLB-985 cells from now on) were a kind gift
from Henry Malech (NIH, Bethesda, USA) [52]. PLB-985 cells were
cultured in suspension at 1 × 106 cells/mL in RPMI at 37 °C with 5%
CO2. The medium was supplemented with 10% fetal bovine serum, 100
units/mL of penicillin and 100 μg/ml of streptomycin. Cells were cen-
trifuged at 1000×g for 10 min, then resuspended in PBS and cen-
trifuged again at 1000×g for 5 min and frozen at −80 °C. PLB-985
frozen pellets were resuspended at a concentration of 2 × 108 cells/ml
in sonication buffer containing 10 mM Hepes (pH 7.4), 10 mM NaCl,
100 mM KCl, 12 mM EGTA, 3.5 mM MgCl2, 1 mM phe-
nylmethylsulfonyl fluoride and supplemented with 2 μM leupeptin,
2 μM pepstatin, and protease inhibitors, just before sonication. The
lysate was centrifuged at 2000 rpm for 5 min at 4 °C, and the super-
natant was collected. The cell pellet was resuspended in sonication
buffer and sonicated again on ice two times. The cell lysate was cen-
trifuged at 2000 rpm for 5 min at 4 °C, and the supernatant was col-
lected. Both supernatants were ultra-centrifuged (200,000×g for
30 min) at 4 °C (Optima MAX-XP Ultracentrifuge, Beckman Coulter).
Protein concentration was assessed by Biuret Assay.
The full length human p67phox, p47phox and the constitutively
active mutant Rac1 Q61L cloned into a pET-30a vector, with a N-
terminal (His)6-tag, were a kind gift from Edgar Pick (Tel Aviv
University, Israel). The recombinant proteins were expressed in E. coli
Rosetta (DE3, pLysS) (Novagen), and bacteria were induced with
0.4 mM isopropyl β-d-thiogalactopyranoside at 18 °C for 16 h. The in-
duced cells were suspended in lysis buffer (20 mM sodium phosphate
J. Reis, et al. Redox Biology 32 (2020) 101466
2
buffer, 0.5 mM NaCl, and 20 mM imidazole, pH 7.4) supplemented with
“Complete” EDTA-free protease inhibitor and 1% (v/v) Triton X-100.
The bacteria were disrupted by sonication, the lysate was centrifuged at
34,000×g for 30 min at 4 °C, and the cleared cell-free extract was fil-
tered through a 0.45-μm filter. The material was applied to Nickel-
Sepharose 6 Fast Flow beads (GE Healthcare), and binding was allowed
to proceed in the batch mode for 60 min on a rotary mixer at room
temperature. The beads were washed with lysis buffer, followed by two
washes with the washing buffer (20 mM sodium phosphate, 0.5 mM
NaCl, and 40 mM imidazole, pH 7.4). The protein bound to the beads
was eluted from the resin with the elution buffer (20 mM sodium
phosphate, 0.5 mM NaCl, and 300 mM imidazole, pH 7.4) at a volume
corresponding to ten times the volume of the beads. To improve the
level of purity the proteins were subjected to further purification by gel
filtration: p67phox on a Superdex 200 Hiload 16/60 fast protein liquid
chromatography (FPLC) column, p47phox and Rac1 Q61L on a
Superdex 75 Hiload 16/60 fast protein liquid chromatography (FPLC)
column. 10-mg amounts of all the proteins were injected into the
column, and chromatography was performed with Lysis buffer without
imidazole, on a High-Pressure Liquid Chromatography (HPLC) system
at a flow rate of 1 ml/min. The purified proteins were supplemented
with 10% glycerol and stored at −80 °C.
Human NOX4 membrane preparation - The cDNAs encoding for the
human NOX4 (isoform 1) and the human p22phox were originally
Fig. 1. The experimental workflow. (A) Chemical structure of reported NOX inhibitors and (B) experimental assays.
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obtained from Genescript. NOX4 was subcloned into a pEG BacMam
vector (a kind gift from Eric Gouaux (Oregon Health and Science
University, Portland)). The construct contained a Kozak sequence, fol-
lowed by a (His)6 tag, an eGFP moiety and a TEV cleavage site at the N-
terminus. P22phox was subcloned into the pDsRed-monomer-N1 vector
with a DsRed moiety at the C-terminus. HEK293-EBNA1-6E cells were
obtained from Yves Durocher (NRC-BRI, Montreal, Canada) [53]. Cells
were grown in suspension using FreeStyle medium (Invitrogen). The
day before transfection, cells were seeded at a density of 5 × 105 cells/
ml. Transient NOX4-p22 co-transfection of HEK293 EBNA-1 was per-
formed using polyethylenimine (linear MW 25000, Polyscience Europe
Gmbh) in a ratio 1:3 (0.6 μg NOX4 vector: 0.4 μg p22 vector: 3 μg
polyethylenimine, per ml of culture). After 24 h, co-transfected cells
were harvested by centrifugation (1200×g, 5 min, 4 °C). Cell pellet was
flash-frozen in liquid nitrogen and stored at −80 °C. Cell viability was
evaluated by Trypan Blue exclusion assay (Trypan Blue solution w/v,
Sigma). The cell pellet was thawed on ice and resuspended in sonication
buffer (20% (v/v) glycerol, 120 mM NaCl, 1 mM EGTA in PBS pH 7.4)
supplemented with protease inhibitors (SigmaFastTM Protease In-
hibitor Cocktail Tablets, EDTA-Free, Sigma-Aldrich) at 4 °C. Cells were
sonicated on ice. The cell lysate was then centrifuged at 500×g for
5 min at 4 °C, and the supernatant transferred in a fresh tube. The cell
pellet was resuspended again in sonication buffer and the sample was
sonicated again on ice. Cell lysate was then centrifuged at 500×g for
5 min at 4 °C, and the supernatant was collected. Both supernatants
were pooled. The supernatant was ultra-centrifuged (160,000×g for
45 min) at 4 °C (Optima MAX-XP Ultracentrifuge, Beckman Coulter).
Finally, the pellet was resuspended and diluted in sonication buffer to a
final protein concentration of at least 30–40 mg/ml measured by the
Biuret assay, aliquoted and stored in the−80 °C freezer. Protein quality
was evaluated by measuring the fluorescence of the eGFP moiety and
the DsRed moiety using fluorescence intensity-based detection on SDS-
PAGE gel (BioRad; ChemiDoc MP imager; Alexa Fluor 488 for eGFP
detection, Alexa Fluor 546 for DsRed detection).
2.3. Evaluation of NOX activity and NOX inhibitors in cell-free assays
Cytochrome c reduction assay on NOX2 and NOX5 membranes – This
assay relies on the reduction of cytochrome c by the NOX-generated
superoxide that can be monitored spectrophotometrically (absorbance
at 550 nm). 156 μg of NOX2-p22 containing membranes were added to
a reaction mixture containing 65 mM sodium phosphate buffer pH 7.0
with 1 mM EGTA, 1 mM MgCl2, 2 mM NaN3, 10 μM FAD, 100 μM LiDS,
160 nM recombinant cytosolic proteins p67phox, p47phox, Rac1 Q61L,
and 200 μM cytochrome c. NOX5 containing membranes (45 μg) using
PBS as assay buffer were added to a reaction mixture containing 2 mM
NaN3, 200 μM FAD, 1 mM CaCl2 and 100 μM cytochrome c. Ligands
were added to the reaction mixture at a concentration of 100 μM and
incubated for 10 min at 25 °C. The reaction was initiated by the addi-
tion of 200 μM NADPH. Measurements were performed using a
ClarioStar plate reader and Cary 100 UV–Vis spectrophotometer.
MCLA assay on NOX2 and NOX5 membranes - MCLA is a chemilu-
minescent (654 nm) reagent that is highly sensitive to superoxide. 20 μg
of NOX2-p22 containing membranes were added to a reaction mixture
containing 65 mM sodium phosphate buffer pH 7.0 with 1 mM EGTA,
1 mM MgCl2, 0.5 μM FAD, 100 μM LiDS, 160 nM recombinant cytosolic
proteins p67phox, p47phox, Rac1 Q61L, and 1 μM MCLA. NOX5-con-
taining membranes (12 μg) were added to a reaction mixture of PBS
with 1 mM CaCl2, 0.5 μM FAD and 1 μM MCLA. Ligands were added to
the reaction mixture at a concentration of 100 μM and incubated for
10 min at 25 °C. The reaction was initiated by the addition of 200 μM
NADPH. Measurements were performed using a GloMax plate reader.
The activities of NOX2 and NOX5 were evaluated also in the absence of
the cytosolic proteins and CaCl2, respectively. SOD was used as an
additional negative control. Control membranes not containing over-
expressed NOX5 were further used to infer the noise-level signals.
Amplex red/peroxidase assay on NOX4 membranes – In this assay,
hydrogen peroxide production is detected through the H2O2-dependent
generation of the Resorufin by horseradish peroxidase. NOX4 con-
taining membranes (100 μg) were added to a reaction mixture of PBS
with 12.5 μM Amplex Red, 0.02 U/ml horseradish peroxidase and
40 μM FAD. The tested compounds (100 μM) were added to the mixture
and incubated for 10 min at 4 °C. The reaction was started by adding
40 μM NADPH, a concentration chosen to minimise interference effects
[54]. Measurements were performed using a ClarioStar plate reader
(excitation 572 nm/emission 583 nm). Catalase as well as membranes
transfected with an empty vector were used as negative control to es-
timate the background signal.
CBA assay on NOX4 membranes – The CBA assay is a fluorescent
assay for the indirect detection of hydrogen peroxide relying on the
enzymatic-independent reaction between hydrogen peroxide and the
non-fluorescent coumarin boronic acid (CBA) with a 1:1 stoichiometry
to form the fluorescent 7-hydroxy-coumarin. NOX4-p22 membranes
(50 μg) were added to the PBS buffer containing 20 μM FAD. The tested
compounds (100 μM) were added to the reaction mixture and incubated
for 10 min at 4 °C. 200 μM CBA and, subsequently, 50 μM NADPH were
added to start the reaction. Measurements were performed using a
ClarioStar plate reader (excitation 320 nm/emission 430 nm). Because
of the lower sensitivity, higher standard deviations were observed with
this assay.
2.4. ROS-scavenging assays
Xanthine Oxidase assay - The inhibitory activity on xanthine oxidase
was evaluated by measuring the effects of the tested inhibitors
(100 μM) on the production of hydrogen peroxide (H2O2) from hy-
poxanthine, using the Amplex Red/Xanthine Oxidase Assay Kit
(Thermofisher Scientific). The tested compounds and adequate amounts
of xanthine oxidase were incubated for 15 min at 37 °C in a flat-black-
bottom 96-well microplate (Thermofisher) with 100 μM Amplex Red
reagent, 0.4 U/mL horseradish peroxidase, and 0.2 mM hypoxanthine.
The production of H2O2 and consequently of resorufin was quantified at
a ClarioStar plate reader based on the fluorescence generated (excita-
tion 530 nm/emission 590 nm).
NADH-PMS assay - Superoxide radicals were generated in a phe-
nazine methosulfate (PMS)-NADH system by oxidation of NADH and
assayed by the reduction of nitroblue tetrazolium. In these experiments,
the superoxide radicals were generated in Tris-HCl buffer (16 mM, pH
8.0) containing 80 μM nitroblue tetrazolium, 70 μM NADH and in-
cubated with the tested compounds (100 μM). The reaction started by
adding 5 μM phenazine methosulfate to the mixture. The reaction
mixture was incubated at 25 °C for 5 min, and then the absorbance was
read at 560 nm using a ClarioStar plate reader. SOD was used as a
positive control. Decreased absorbance of the reaction mixture com-
pared to the negative control indicated superoxide-scavenging activity
from the tested compounds.
2.5. Kinetics evaluation of NOX inhibitors on the purified NOX5
dehydrogenase domain
The inhibitory activity of the tested compounds on the purified C.
stagnale dehydrogenase domain was measured using 1 μM protein in a
final volume of 130 μL of 50 mM Hepes pH 7.5 (and 300 μM FAD in the
case of the wild-type protein) in a Cary 100 UV–visible spectro-
photometer (Varian) equipped with a thermo-stated cell holder
(T = 25 °C). Reaction rates were determined by following NADPH
oxidation at 340 nm.
2.6. Microscale thermophoresis binding assay on purified NOX5
dehydrogenase domain
NOX5 dehydrogenase domain-suramin interactions were
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characterized by microscale thermophoresis. The ligand was titrated to
a maximum concentration of 6.4 mM using a fixed concentration of the
fluorescently labelled protein (~200 nM). Sixteen serially diluted ti-
trations of suramin were prepared to generate one full binding iso-
therm. All binding reactions were carried out in a buffer containing
Hepes 50 mM, NaCl 240 mM, 0.5% glycerol, 250 μM FAD and 0.1%
pluronic acid at pH 7.5. Samples were loaded into NT.115 premium
treated capillaries (Nanotemper Technologies) after the reaction was
incubated at 25 °C for 10 min. Consequently, the samples were mounted
in the Monolith NT.115 apparatus (Nanotemper Technologies) for
binding measurements. The data for microscale thermophoresis ana-
lysis were recorded at 25 °C. All binding experiments were followed
using a red fluorescence channel (red filter; excitation 605–645 nm,
emission 680–685 nm). Data analysis was performed with software
NTAffinityAnalysis (Nanotemper Technologies) where the binding iso-
therms were derived from the raw fluorescence data. The experiments
Fig. 2. Characterization of NOXs. (A) Michaelis-Menten curve of NOX5 membranes using the cytochrome c reduction assay. (B) Superoxide generation by bacterial
NOX5 using the MCLA assay. (C) Michaelis-Menten curve of human NOX2-p22 membranes using the cytochrome c reduction assay. (D) Superoxide generation by
NOX2 using the MCLA assay. (E) Western-blot analysis of PLB-985 cell membranes by immunoblotting with NOX2 (54.1) and p22 monoclonal (44.1 antibodies). The
arrows indicate the highly glycosylated 91 kDa NOX2, and the non-glycosylated 22 kDa p22 (lane 1: molecular weight marker; lane 2: NOX2-p22 containing
membranes after separation on 12% polyacrylamide gel electrophoresis). (F) Michaelis-Menten curve of human NOX4-p22 HEK293 membranes using the Amplex
Red-peroxidase assay. (G) Hydrogen peroxide generation by NOX4 and corresponding controls using the Amplex Red-peroxidase coupled assay. Full NADPH sa-
turation could not be achieved because of assay interference. (H) In-gel fluorescence analysis of HEK cells heterologously expressing eGFP-NOX4 (predicted 96 kDa)
and DsRed-p22 (predicted 50 kDa) expressing membranes. As often observed for membrane proteins, both fusion proteins display anomalous migration in a SDS
PAGE due their hydrophobicity. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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Fig. 3. Activities of the NOX inhibitors (100 μM) evaluated on (A) bacterial NOX5, (B) human NOX2, and (C) human NOX4 membrane preparations.
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were performed in triplicate and the resulting standard deviation cal-
culated with NTAffinityAnalysis.
2.7. Thermal shift analysis on purified NOX5 dehydrogenase domain
Thermostability assays on wild-type dehydrogenase domain were
performed on a TychoTMNT.6 system (NanoTemper Technologies
GmbH, Munich, Germany) to assess the effect of the tested ligands on
the stability of the purified protein. The experiments were conducted in
the absence and presence of ligands. The samples were heated up from
35 °C to 95 °C for the duration of 3 min and their inflection point (Ti)
was determined.
2.8. Characterization of DPI binding to NOX5
With regard to the flavin component, 20 μM of dehydrogenase
proteins were reduced with 200 μM NADPH and incubated in the pre-
sence and absence of 200 μM DPI. UV–Vis spectra were recorded with
Agilent Diode Array at 25 °C. With regard to the heme component, the
experiments were carried out on the purified wild-type and R256S
transmembrane domain of bacterial NOX5. An excess of sodium di-
thionite was mixed with 6 μM protein in the storage buffer. DPI (1 mM)
was added to the solution in order to determine the ligand effect on the
heme group of the protein. UV–Vis spectra were recorded with Agilent
Diode Array at 25 °C. MS analysis was carried out upon heme extraction
in an organic solvent. 30 μM of purified wild-type transmembrane do-
main of NOX5 was reduced with an excess of sodium dithionite, dis-
solved in the mixture acetonitrile:1.7 M HCl (8:2 vol/vol) and left
stirring at room temperature for 20 min. The reaction was quenched by
addition of MgSO4 and NaCl. The mixture was vortexed and then cen-
trifuged for 5 min at 2500×g to separate the unfolded protein from the
extracted heme. The same procedure was followed for the reduced
transmembrane domain in the presence of 2 mM DPI. 10 μL of each
extract sample were analysed by ESI-MS using a LCQFleet Thermo
Scientific Ion Trap.
2.9. Characterization of VAS inhibitor binding to NOX5 by ESI-MS
1 μM wild-type or C668S mutant dehydrogenase domain (untreated
or after incubation with VAS2870 or VAS3947) dissolved in a mixture
of acetonitrile/water/formic acid 0.1% was analysed by ESI-MS using a
LCQFleet Thermo Scientific Ion Trap.
2.10. Statistical analysis
All graphs were prepared using GraphPad Prism™ and all data are
expressed as mean ± standard deviation. Sigmoidal curve-fitting of
concentration-response curve, IC50-values and statistical tests were all
performed with GraphPad Prism™. Concentration-response curves are
presented as % of the control, with control being the untreated condi-
tion. For Ki determination, initial velocities obtained at multiple
NADPH and inhibitor concentrations were fitted globally to competi-
tive, uncompetitive and noncompetitive models. The best-fit model was
identified based on the R2 parameter given by GraphPad Prism™ soft-
ware (GraphPad Software, Inc., San Diego, CA).
3. Results and discussion
3.1. Characterization of NOXs and evaluation of their catalytic activity
Our work relied on testing each compound on three NOX isoforms;
human NOX2 membranes obtained from cultured PLB-985 cells, human
NOX4 membranes from enzyme over-expressing HEK293 EBNA-1 cells,
and Cylindrospermum stagnale NOX5 over-expressed in E. coli cell
membranes (Fig. 2). We chose the C. stagnale NOX5 because it was
successfully used for structural studies and is 40% identical in sequence
to human NOX5 and two of its domains, dehydrogenase and trans-
membrane, are available in purified forms [5]. The enzymatic activities
were evaluated using several methods: the cytochrome c reduction and
MCLA assays were employed for the superoxide-producing NOX5 and
NOX2 whereas the hydrogen peroxide-producing NOX4 was evaluated
using a peroxidase-coupled and CBA assays. Under our experimental
conditions, NOX5 displayed a KMNADPH of 101.4 ± 7.6 μM and a Vmax
of 0.159 ± 0.003 mM min−1 (Fig. 2A) whereas NOX2 showed a
KMNADPH of 6.6 ± 1.4 μM and a Vmax of 0.48 ± 0.02 mM min−1
(Fig. 2D). The analysis of NOX4 resulted in a KMNADPH of
156.5 ± 35.4 μM and a Vmax of 4524 ± 642 pM min−1, confirming
the lower activity of this isoform (Fig. 2F) [1–3].
3.2. Initial evaluation of NOX inhibitors
A total of 24 known NOX inhibitors were tested using a standardized
protocol that would enable a close comparison of their anti-NOX ac-
tivities. As many of these compounds were reported to be effective at
single- or double-digit μM concentrations [28,31,38,39], we chose to
probe them at 100 μM concentrations using 40–200 μM NADPH
(Figs. 1A and Fig. 3A–C). A few molecules displayed full (suramin,
ebselen, celastrol and DPI) or moderate (ML-090; 40–50%) inhibition
on all NOXs. Differently from these pan-inhibitors, the other com-
pounds featured some selectivity. The tat-gp91ds peptide strongly in-
hibited NOX2, as expected in light of its capacity to interfere with the
enzyme activation [41]. The six tested phenothiazine derivatives and
GSK2795039 displayed pronounced inhibition (> 60%) of NOX2 and
NOX4 whereas NOX5 was affected only when assayed with the MCLA-
based protocol. VAS2870 and perhexiline displayed low-to-sustained
(40–70%) inhibitions against NOX2 and NOX4 but not against NOX5.
VAS3947 was active only against NOX4. Atorvastatin was instead active
mostly on NOX5 (~50%) whereas the pyrazoline compound featured
significant (> 40% inhibition) activity only against NOX4. The other
compounds exhibited more scattered patterns of inhibition with strong
dependencies on the assays. Thus, GKT136901 and GKT137831 proved
to be strong NOX4 inhibitors but moderately active against NOX2 and
NOX5 only when assayed with MCLA. Likewise, imipramine blue,
imipramine chloride, plumbagin, and phenanthridinone displayed
assay-dependent inhibitory activities. Collectively, our initial survey
demonstrated that most compounds do indeed feature the NOX in-
hibitory activities under the tested conditions. However, these activities
often depend on the assay being used.
3.3. Evaluation of assay interferences and ROS-scavenging effects
NOX inhibition assays are prone to artefacts that may arise from
redox and ROS-scavenging activities of the investigated compounds
and/or interference with the reagents used in the enzymatic assays
[27–31]. With regard to superoxide, scavenging was verified by a non-
enzymatic assay whereby the superoxide generated by the reaction of
phenazine methosulfate with NADH reacts with nitroblue tetrazolium
to generate a colourful compound (absorption at 560 nm). As for hy-
drogen peroxide, we employed the H2O2-producing xanthine oxidase
and its hypoxanthine substrate using the Amplex Red/peroxidase assay.
Overall, most of the studied compounds displayed no significant in-
terference with superoxide. The only exceptions were suramin, which
proved to be a strong superoxide scavenger in agreement with previous
data [55], and fluphenazine, perphenazine and 6(5H)-phenan-
thridinone, which showed some mild scavenging activities (Fig. 4A).
The H2O2-interfering activities were instead more pervasive. Three
phenothiazine derivatives (fluphenazine, perphenazine and proma-
zine), ebselen, celastrol, DPI, 3-methyl-1-phenyl-2-pyrazoline,
GKT137831 and ML090 showed powerful inhibitions of the hydrogen
peroxide-producing activity of xanthine oxidase (Fig. 4A). These effects
could arise from the direct inhibition of xanthine oxidase, the inhibition
of the horseradish peroxidase used in the assay, interference with the
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Amplex Red probe, or a direct H2O2-scavenging effect. In order to
clarify this issue and to further explore the redox reactivities of the
tested compounds, we performed two additional assays. In the first one,
the effect of the anti-NOX compounds on the spontaneous auto-oxida-
tion of the MCLA probe was used as an indicator of some redox and/or
off-target effect. In the second assay, the Amplex Red/peroxidase assay
was executed by directly adding the inhibitors in the absence of a NOX
enzyme (but in the presence of NADPH) to probe for interference with
Amplex Red (Fig. 4B). The six phenothiazines, ebselen, GSK2795039,
GKT136901 and GKT137831 showed a substantial interference in both
assays. Moreover, celastrol and perhexiline interfered with the MCLA
auto-oxidation whereas ML090 and the two imipramins displayed po-
tent assay interference on the Amplex Red/peroxidase assay. Finally,
we notice that the inhibition of MCLA auto-oxidation by tat-gp91ds is
probably not surprising, because this peptidic inhibitor comprises a
cysteine that can afford a mild anti-oxidant effect (Fig. 1A). These re-
sults were striking because all anti-NOX compounds showed some de-
gree of assays interference, with the only exception of VA2870 and
VAS3947.
3.4. Inhibitor evaluation and validation using the purified dehydrogenase
domain of NOX5
The outcome of the previous experiments indicated that the in-
hibitory activity of many of the tested compounds may well arise, in
part or completely, from assay interference and/or ROS-scavenging
activities. To further investigate the issue, we relied on the purified
dehydrogenase domain of the bacterial NOX5, which can be expressed
as stand-alone protein and is capable to oxidise NADPH using its FAD
prosthetic group and oxygen as electron acceptor [5]. This enzymatic
activity can be easily measured by a spectrophotometric NADPH-de-
pletion assay to ascertain if certain compounds might function as
competitive inhibitors by hindering access of the NADPH substrate. A
low-activity domain mutant, where an engineered tryptophan side
chain at the C-terminus occupies the binding site for the nicotinamide
of NADPH, was used to corroborate the mechanism of inhibition
(Fig. 5A) [5]. In fact, inhibitors selectively interfering with NADPH
binding should be much more active on the wild-type dehydrogenase
than on this mutant protein.
Fig. 4. Evaluation of ROS-scavenging and assay-interfering activities of NOX-inhibitors (100 μM) probed by (A) xanthine oxidase and phenazine methosulfate (PMS)-
NADH assays and (B) MCLA auto-oxidation and peroxide-coupled assays.
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Only 7 compounds featured significant (> 40%) inhibition of the
isolated dehydrogenase domain (Fig. 3A). This finding was in sharp
contrast with the widespread inhibitions observed against the full-
length NOX5. Furthermore, 5 of the 7 hits (suramin, ebselen, celastrol,
GSK2795039 and GKT831) displayed similar or identical degree of in-
hibition towards both wild-type and mutant dehydrogenase (Fig. 5B).
Such a lack of selectivity, combined with the lack of any stabilising
effect in thermal shift analysis (Supplementary Fig. 1), supported the
notion that the inhibition exerted by these compounds is unlikely to
arise from a specific interaction with the protein (e.g. with its NADPH-
binding site) but rather from their previously-described non-specific
effects (see Fig. 4A–B). This concept was validated by additional ex-
periments on suramin. When assayed against the wild-type dehy-
drogenase domain, this compound showed uncompetitive inhibition
with a sub-micromolar inhibition constant (Ki = 0.39 ± 0.05 μM).
However, when tested with microscale thermophoresis, suramin fea-
tured a 1000-fold lower affinity, which likely reflects its propensity for
protein-binding due to its heavily charged structure (Kd = 52.2 ±
1.1 μM; Supplementary Fig. 2). Beside these observations, a more en-
couraging pattern of data emerged from the characterization of
VAS2870 and VAS3947, the other two compounds that proved to be
strong dehydrogenase domain inhibitors. These anti-NOX and “non-in-
terfering” (Figs. 3–4) compounds displayed minimal inhibition
(20–30%) against the mutant dehydrogenase as opposed to the 100%
inhibition towards the wild-type dehydrogenase (Fig. 5B). This result
was particularly informative as it was suggestive of a specific effect of
VAS compounds to the dehydrogenase active site, as opposed to the
non-specific effects featured by all other dehydrogenase inhibitors.
3.5. Specific NOX inhibitors and their mechanism of action
The extended analysis described in the previous paragraphs led to
the conclusion that the DPI, VAS2870 and VAS3947, and tat-gp91ds are
the most convincing bona fide antagonists of NOXs. As listed in Table 1,
IC50 measurements proved them as effective low-micromolar or
nanomolar NOX inhibitors while being mostly devoid of significant
assay-interference or ROS-scavenging effects though DPI inhibits xan-
thine oxidase (a flavoenzyme) and the Cys-containing tat-gp91 inter-
feres with MCLA (Fig. 4B). At this point, it is important to remark that
we do not at all rule out that other compounds among our pool of in-
vestigated molecules may directly engage NOXs. However, the pro-
nounced scavenging and interfering effects observed by us and others
will inevitably confuse the evaluation of their bona fide binding and
inhibitory activity (if any). For instance, we found that GSK2795039
displays a very low IC50 for NOX2 (0.0367 ± 0.0013 μM) but this
value factors in the non-specific scavenging and interfering activities of
this compound, as discussed above and in agreement with previous
findings [27–31].
Based on these data, we sought to clarify the inhibition mechanism
of DPI and the VAS compounds by exploiting recombinant full-length
NOX5 and its isolated domains as model enzymes for pharmacological
and biophysical studies.
3.5.1. DPI targets the reduced state of the NOX prosthetic groups
The powerful inhibition of full-length NOX5 by DPI was confirmed
by kinetic studies on the purified protein, which displayed an un-
competitive inhibition with a Ki = 0.98 ± 0.14 μM (Supplementary
Fig. 3). Previous studies suggested that the main target of DPI are the
heme groups of NOXs [19]. We sought to experimentally proof this
hypothesis by using the recombinant purified transmembrane domain
of NOX5 [5]. We first noticed that the oxidised heme spectrum is not
perturbed by DPI (Fig. 6A). By contrast, when DPI was added to the
dithionite-reduced protein, the rapid quenching of the heme absor-
bance at 427 nm and of the α-band at 558 nm was observed (Fig. 6A).
After re-oxidation (upon consumption of dithionite following its reac-
tion with DPI), the spectrum of the heme remained quenched. These
experiments demonstrated that DPI reacts with the reduced trans-
membrane domain, possibly forming an adduct with heme. Next, this
same experiment was performed with the low-activity Arg256Ser
transmembrane mutant, which targets a conserved arginine side chain
in the oxygen-binding site, adjacent to the extra-cellular heme of the
protein [5]. The mutant yielded virtually the same result observed for
the wild-type domain, showing that DPI binding does not depend on the
fine structure of the heme-binding site (Fig. 6A). We further in-
vestigated this feature by HPLC/ESI-MS. Organic extraction carried out
on the protein reduced with dithionite and treated with excess of the
ligand, did not reveal any difference in the heme spectrum when
compared to the spectrum measured on the protein not treated with DPI
(Supplementary Fig. 4). Therefore, though stable in the protein en-
vironment, the DPI-heme adduct is reversible as it cannot withstand the
extraction from the protein. We hypothesise that the adduct involves
the formation of a σ-coordination complex between a phenyl group of
DPI and the iron as proposed for other heme enzymes treated with
heme-reacting compounds and featuring similar spectroscopic proper-
ties [56,57].
In addition to the established role as heme ligand, there is ample
evidence in the literature that DPI can also bind to flavoproteins
[17,58]. We indeed found that DPI strongly and uncompetitively in-
hibits the low-activity mutant of the NOX5 dehydrogenase domain
Fig. 5. The dehydrogenase domain of NOX5 as model system for inhibition
studies. (A) The dehydrogenase active site. Trp695 (green) is the stabilising
amino acid belonging to the extension PWLEL added to the C-terminus (PDB
5O0X). (B) Inhibition studies (100 μM inhibitors) on the wild-type and C-
terminal mutant dehydrogenase. (For interpretation of the references to colour
in this figure legend, the reader is referred to the Web version of this article.)
Table 1
IC50 determination for selected NOX inhibitors.
IC50 bacterial NOX5
(μM)
IC50 human NOX2
(μM)
IC50 human NOX4c
(μM)
DPI 3.28 ± 1.32a 0.0562 ± 0.017a 2.26 ± 1.18
tat-gp91ds Inactive at 100 μMb 10.3 ± 1.2b Inactive at 100 μMb
VAS3947 Inactive at 100 μMa Inactive at 100 μMa 31.9 ± 24.3
a IC50 determination using the MCLA assay.
b IC50 determination using the cytochrome c reduction assay.
c IC50 determination with the Amplex Red/HRP peroxidase assay.
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(αKi =0.42 ± 0.06 μM) though the inhibition of the wild-type domain
is 200-fold weaker (αKi = 127 ± 13 μM; Supplementary Fig. 5). The
pronounced inhibition by DPI of the mutant dehydrogenase is probably
explained by the tightly bound FAD, that is retained by the protein even
during purification, differently from the wild-type domain that instead
requires the addition of exogenous FAD (300 μM) to allow activity
measurements. The mutant dehydrogenase was therefore chosen for
further mechanistic studies. We first noticed that the addition of
NADPH leads to the fast reduction of the flavin. The prosthetic group is
then slowly re-oxidised with concomitant consumption of NADPH
(absorbance at 340 nm). However, upon re-oxidation, the wavelength
of the absorbance peak characteristic of the oxidised flavin shifted from
462 nm to 450 nm (Fig. 6B). The latter wavelength peak corresponds to
free FAD, demonstrating that the enzyme tends to release the FAD after
its reduction. We then performed the same experiment in the presence
of DPI. The incubation with the inhibitor did not affect the spectrum of
the oxidised protein but, differently from the un-inhibited domain, no
re-oxidation was observed after NADPH addition (Fig. 6B). These ob-
servations resemble previous findings on other flavoproteins treated
with DPI: both flavin reduction by NADPH and retention of the flavin
by the enzyme are necessary for DPI to react and afford inhibition
through a stable reduced flavin-DPI adduct [17,58]. This mechanism is
consistent with the observed pattern of uncompetitive inhibition and
explains why the poorly FAD-retaining wild-type dehydrogenase is
hardly affected by DPI. In summary, the NOX inhibition by DPI arises
from its relatively non-specific reaction with the reduced states of both
flavin and heme cofactors, possibly with a preponderant contribution of
the two heme groups.
3.6. VAS2870 and VAS3947 alkylates a conserved active-site cysteine
VAS2870 and VAS3947 displayed very significant potency on the
wild-type dehydrogenase domain of NOX5 with IC50 of
0.257 ± 0.106 μM and 6.09 ± 1.41 μM, respectively (Supplementary
Fig. 6). In the course of the evaluation of these compounds, we con-
sidered their intense absorbance at 280 nm and noticed that it con-
tributed to the absorbance of purified inhibited proteins that showed a
higher absorbance after gel-filtration. This observation led us to hy-
pothesise the formation of an adduct between the compounds and the
enzyme, following previous literature indicating that VAS compounds
can react with protein cysteines [59]. The gel-filtered proteins with or
without VAS2870 were thereby analysed by ESI-MS. The results were
unambiguous in that a 210 Da increase in the inhibitor-treated protein
molecular weight was observed. This was fully consistent with the al-
kylation of a cysteine's thiol by the benzyl-triazolopyrimidine moiety
(210 Da) of VAS2870, while the benzoxazoyl group acted as a leaving
group (Fig. 7A). The same was observed for VAS3947, encompassing an
oxazolyl ring as a leaving group, thus leaving a molecule of 210 Da
covalently bound to the dehydrogenase domain (Fig. 7A).
Having showed that VAS2870 and VAS3947 act as covalent ligands
of the dehydrogenase domain, we sought to identify which cysteine was
involved in the covalent binding. The dehydrogenase domain of C.
stagnale NOX5 contains four cysteines [5]. We focused on a conserved
cysteine present in the active site as the one which could be targeted by
the VAS derivatives (Cys668; Fig. 5A). Accordingly, we performed
mutagenesis to replace Cys688 by a serine. The purified mutant ex-
hibited Michaelis-Menten parameters (KMNADPH = 6.8 ± 1.5 and
Kcat = 20 ± 2 min−1) similar to those of the wild-type protein
(KMNADPH = 12 ± 3 μM, Kcat = 56 ± 5 min−1) [5]. Most interest-
ingly, enzymatic assays performed with both VAS derivatives showed
that the compounds could not inhibit the mutant domain. Consistently
with this observation, we observed no increase in the mutated protein
molecular weight upon incubation with the inhibitors, demonstrating
that no adduct is formed in absence of Cys688 (Supplementary Fig. 7).
Importantly, the targeted cysteine is absolutely conserved among NOXs.
Indeed, VAS2870 and VAS3947 are powerful NOX4 inhibitors (Table 1
and Fig. 3). The potency of the inhibition increases with the time of
incubation, as it can be expected from poorly soluble
(logPVAS2870 = 3.6) covalent inhibitors. Consistently, with sufficiently
long incubation times, also the inhibition of NOX2 and NOX5 became
significant (Fig. 7B). The higher sensitivity to VAS compounds by the
isolated dehydrogenase domain of NOX5 compared to the full-length
protein (Table 1; Fig. 7; Supplementary Fig. 6) likely reflects a de-
creased reactivity and/or accessibility of the active-site cysteine when
the domain is embedded in the membrane environment of the full-
length protein. Interestingly, a role of this conserved residue in enzyme
regulation has been suggested for the plant NOX5 orthologue RBOHD
[60]. The key conclusion from these experiments is the demonstration
of the VAS derivatives as direct active-site modifiers of NOXs.
Fig. 6. DPI targets the NOXs' prosthetic groups. (A) UV–visible absorption spectra of the oxidised (left), reduced (middle), and reduced R256S (right) NOX5's
transmembrane domain after incubation with DPI. Protein reduction was achieved by adding dithionite that absorbs at 315 nm. (B) UV–visible absorption spectra of
the mutant NOX5 dehydrogenase after incubation with NADPH (left) and NADPH plus DPI (right).
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4. Conclusions
Development of NOX inhibitors is especially challenging because
many chemicals have redox and ROS-scavenging activities. These fea-
tures have to be critically evaluated in order to deconvolute the in-
hibition arising from the specific binding of a compound to functional
site(s) of the protein from non-specific effects. Considering the major
role played in pathophysiological states by NOXs and, more in general
by ROS, it seems paramount to assess the ROS-scavenging properties of
any novel drug under development. Our survey of two dozen known
anti-NOX compounds revealed that the vast majority of them feature
assay-interfering and ROS-scavenging properties. We suspect that these
non-specific effects greatly contribute to their (in many cases strong)
NOX inhibition capacity. Our work also showed that orthogonal assays
on different NOX isoforms and domains, together with recently devel-
oped technologies to probe protein-ligand binding, can effectively help
to clarify the mode of inhibition by a target compound. DPI is firmly
demonstrated to engage the heme and possibly the flavin cofactors. This
compound suffers from many limitations because it acts on many tar-
gets and it is redox reactive. Nevertheless, it also features valuable
properties. Its mode of inhibition (i.e. reacting only with the reduced
prosthetic groups) implies that it will act only on activated NOXs. In
addition, it may be the prototype of compounds that do not need to
enter cell by targeting the ROS-producing heme on the external side of
the cell-membrane. VAS2870 and VAS3947 demonstrate that a con-
served active-site cysteine can be targeted for effective covalent in-
hibition. Importantly, this mode of inhibition affects the first step of the
reaction (NADPH binding and FAD reduction), blocking NOXs at the
beginning of their catalytic cycle. These findings open new avenues
towards powerful and selective NOX inhibitors.
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